Precision Biosciences (DTIL) Total Current Liabilities (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Total Current Liabilities data on file, last reported at $7.8 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 37.42% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 37.42% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 40.5% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.8 million, down from $8.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for DTIL reached as high as $61.1 million in Q3 2022 and fell as low as $7.8 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $32.9 million across 5 years, with a median of $33.0 million in 2024.
• Across the five-year window, Total Current Liabilities surged 67.64% in 2022 and plunged 76.33% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $59.7 million in 2022, then dropped by 16.22% to $50.0 million in 2023, then plunged by 70.03% to $15.0 million in 2024, then plunged by 40.5% to $8.9 million in 2025, then slipped by 12.99% to $7.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $7.8 million in Q1 2026, $8.9 million in Q4 2025, and $15.0 million in Q3 2025.